3-ethyl-2-methyl-2-thiopseudourea hydroiodide | 7204-32-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 异硫脲类
• 英文名称: 3-ethyl-2-methyl-2-thiopseudourea hydroiodide
• 英文别名: S-Methyl-N-ethyl-isothioharnstoff；1-ethyl-S-methylisothiourea hydroiodide；N-ethyl-S-methyl-isothiourea; hydriodide；N-Aethyl-S-methyl-isothioharnstoff; Hydrojodid；1-ethyl-2-methyl-isothiourea hydroiodide；[Amino(methylsulfanyl)methylidene]-ethylazanium;iodide
• CAS: 7204-32-2
• 化学式: C₄H₁₀N₂S*HI
• 分子量: 246.115
• InChiKey: KGGGDOUUGUNODJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  63.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-ethyl-2-methyl-2-thiopseudourea hydroiodide 在 sodium hydrogen selenide 作用下， 以 乙醇 为溶剂， 生成 ethyl-selenourea
  参考文献：
  名称：

  Synthesis of selenoureas and selenothiocarbamic esters from thioureas

  摘要：

  DOI：

  10.1021/jo01263a070
• 作为产物：
  描述：

  乙基硫脲 以 丙酮 为溶剂， 生成 3-ethyl-2-methyl-2-thiopseudourea hydroiodide
  参考文献：
  名称：

  Substituted guanidinedicarbonyl derivatives

  摘要：

  这份披露描述了新型的取代胍二羰基衍生物，具有抗焦虑活性，并且也可作为治疗哺乳动物认知和相关神经行为问题的药物。

  公开号：

  US04977189A1

文献信息

• [EN] ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS<br/>[FR] DÉRIVÉS DE CARBOXAMIDINE DE PYRAZOLINE ARYLSULFONYLIQUE FORMANT DES ANTAGONISTES DE 5-HT6
  申请人：SOLVAY PHARM BV

  公开号：WO2009115515A1

  公开（公告）日：2009-09-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5- HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  这项发明涉及芳基磺酰基吡唑啉羧酰胺衍生物作为5-HT6受体拮抗剂，以及用于制备这些化合物的方法和用于它们合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们在向患者施用以达到在帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑、抑郁症、躁郁症、精神病、癫痫、强迫性障碍、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、暴食症、暴食症、恐慌发作、不安定症、注意力缺陷多动障碍、注意力缺陷障碍、戒除可卡因、乙醇、尼古丁或苯二氮卓类药物滥用、疼痛、与脊柱损伤或头部损伤相关的障碍、脑积水、功能性肠道障碍、肠易激综合征、肥胖和2型糖尿病中的治疗效果方面的应用。这些化合物具有一般公式（1），其中符号的含义如描述中所示。
• Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction
  作者：Jun Wang、Yan Wang、Zhenyu Li、Peng Zhan、Rujun Bai、Christophe Pannecouque、Jan Balzarini、Erik Clercq、Xinyong Liu

  DOI：10.2174/1573406410666140306151815

  日期：2013.11.28

  The interaction between the HIV-1 transactivator protein Tat and RNA response element (TAR) plays a critical role in HIV-1 transcription. Based on the pharmacophore model of reported inhibitors, a series of novel substituted guanidine indole derivatives was designed, synthesized and evaluated for their in vitro HIV-1 and HIV-2 inhibitory activity using the IIIB strain and ROD strain, respectively. Preliminary biological evaluation indicated that three compounds exhibited marked inhibitory activity against HIV-1 IIIB. Quite unexpectedly, compound a-7 was also endowed with the moderate anti-HIV-2 potency (EC50 = 58.14 µM). In addition, preliminary discussion on the activity results and molecular modeling of these new analogues were presented in this manuscript.

  HIV-1 转录激活蛋白 Tat 与 RNA 反应元件 (TAR) 之间的相互作用在 HIV-1 转录过程中起着至关重要的作用。根据已报道抑制剂的药理模型，设计、合成了一系列新型取代胍吲哚衍生物，并分别使用 IIIB 株和 ROD 株对其体外 HIV-1 和 HIV-2 抑制活性进行了评估。初步生物评估表明，三种化合物对 HIV-1 IIIB 具有明显的抑制活性。出乎意料的是，化合物 a-7 还具有中等程度的抗 HIV-2 效力（EC50 = 58.14 µM）。此外，本手稿还对这些新类似物的活性结果和分子模型进行了初步讨论。
• 3-Hydroxy-3-(1,2,5-thiadiazolyloxyalkanol)-3,4-dihydro-2H-1,5-ben
  申请人：Merck & Co., Inc.

  公开号：US03944560A1

  公开（公告）日：1976-03-16

  3-Hydroxy-3-(substituted-aminoalkyl-3,4-dihydro-2H-1,5-benzodioxepin products are described that exhibit .sym.-advenergic stimulating properties and are therefore suitable for use as bronchodilating agents. The products are prepared essentially by four principal routes from 3-oxo-3,4-dihydro-2H-1,5-benzodioxepins. By one route the 3-oxobenzodioxepin is treated with a nitroalkane to give a 3-hydroxy-3-nitroalkyl-benzodioxepin the nitro group of which is reduced to an amine and the resulting compound reacted with an aldehyde or ketone under hydrogenating conditions to introduce the desired substituent into the amino function. By a second route the 3-oxobenzodioxepin is reacted with an alkali metal nitrile to form the cyanhydrin which upon reduction forms the 3-hydroxy-3-aminoalkyl-benzodioxepin that can be treated with a ketone or aldehyde to give the desired products or can be reacted with sodium nitrite or other agent to form a 3-spiro-benzodioxepin-2-oxirane which upon reaction with an amine provides the desired product. The 3-spiro-benzodioxepin-2'-oxirane also can be obtained by treatment of the 3-oxo-benzodioxepin with a sulfurylide, A fourth method involves forming a benzodioxepin-3-spiro-5'-oxazolidin-2'-one which upon treatment with dilute alkali gives the desired 3-hydroxy-3-(substituted aminoalkyl)-3,4-dihydro-2H-1,5-benzodioxepin The intermediate oxazolidinone compounds can be treated if desired with various agents to attach substituents on the benzenoid moiety of the starting substance. These oxazolidinones exhibit .beta. -stimulating and skeletal muscle relaxant properties.

  描述了具有β-肾上腺素能兴奋作用的3-羟基-3-(取代氨基烷基)-3,4-二氢-2H-1,5-苯并二氧杂环庚烷产品，因此适用于用作支气管扩张剂。这些产品基本上通过从3-氧代-3,4-二氢-2H-1,5-苯并二氧杂环庚烷经四种主要途径制备而成。其中一种途径是将3-氧代苯并二氧杂环庚烷与硝基烷反应，得到3-羟基-3-硝基烷基苯并二氧杂环庚烷，其硝基还原为胺基，然后在氢化条件下将所得化合物与醛或酮反应，以引入所需的取代基到氨基功能中。第二个途径是将3-氧代苯并二氧杂环庚烷与碱金属腈反应，形成氰水合物，还原后形成3-羟基-3-氨基烷基苯并二氧杂环庚烷，可以用酮或醛处理以得到所需的产物，或者可以与亚硝酸钠或其他试剂反应形成3-螺-苯并二氧杂环庚烷-2-环氧烷，再与胺反应以提供所需的产物。也可以通过用磺酰亚胺处理3-氧代苯并二氧杂环庚烷来获得3-螺-苯并二氧杂环庚烷-2'-环氧烷。第四种方法涉及形成苯并二氧杂环庚烷-3-螺-5'-噁唑烷-2'-酮，该化合物在稀碱处理下可得到所需的3-羟基-3-(取代氨基烷基)-3,4-二氢-2H-1,5-苯并二氧杂环庚烷。如果需要，在中间噁唑烷酮化合物上可以用各种试剂处理以在起始物质的苯环部分附加取代基。这些噁唑烷酮化合物表现出β-肾上腺素能兴奋和骨骼肌松弛作用。
• ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Loevezijn Arnold Van

  公开号：US20110046171A1

  公开（公告）日：2011-02-24

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及芳基磺酰基吡唑啉羧酰胺衍生物，其作为5-ht6受体拮抗剂，以及用于制备这些化合物的方法和有用于它们的合成的新型中间体。该发明还涉及这些化合物和组合物的用途，特别是它们用于给患者治疗帕金森病、亨廷顿病、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚症候群、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓创伤或头部损伤有关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病。这些化合物具有通式（1），其中符号的含义如描述中所给。
• Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists
  申请人：Van Loevezijn Arnold

  公开号：US08563723B2

  公开（公告）日：2013-10-22

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及苯磺酰基吡唑啉羧酰胺衍生物作为5-ht6受体拮抗剂，以及制备这些化合物的方法和用于它们合成的新型中间体。本发明还涉及这些化合物和组合物的用途，特别是将它们用于治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮卓类药物的疼痛、与脊髓损伤或头部损伤相关的疾病、脑积水、功能性肠道疾病、肠易激综合征、肥胖症和2型糖尿病等疾病。这些化合物具有通式（1），其中符号的含义如描述中所示。